Sarepta Therapeutics (SRPT) Return on Capital Employed (2011 - 2026)
Sarepta Therapeutics (SRPT) recorded quarterly Return on Capital Employed of 1.48% in Q1 2026, up 95.08% quarter-over-quarter from 30.08% in Q4 2025, and up 229.0% on a YoY basis from 0.45% in Q1 2025.
Sarepta Therapeutics (SRPT) Return on Capital Employed (2011 - 2026) Analysis & Trends
Sarepta Therapeutics' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 1.48% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 229.0% year-over-year to 1.48%; the TTM figure through Mar 2026 stood at 1.48% (up 229.0% YoY), while the FY2025 annual figure was 27.32%, down 3489.0% from the prior year.
- Return on Capital Employed was 1.48% for Q1 2026 at Sarepta Therapeutics, up from 30.08% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 7.15% in Q4 2024 to a low of 30.08% in Q4 2025.
- Historically, Return on Capital Employed has averaged 10.35% across 5 years, with a median of 10.57% in 2023.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed soared 2109 bps in 2024, then sank 3723 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 21.26% in 2022, then jumped by 50 bps to 10.57% in 2023, then surged by 168 bps to 7.15% in 2024, then slumped by 521 bps to 30.08% in 2025, then jumped by 95 bps to 1.48% in 2026.
- The last three Return on Capital Employed figures came in at 1.48% (Q1 2026), 30.08% (Q4 2025), and 4.75% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Sarepta Therapeutics | 1.84 Bn | 1.16 Bn | 291.52 Mn | -1.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.48% |
| Dec 31, 2025 | -30.08% |
| Sep 30, 2025 | -4.75% |
| Jun 30, 2025 | -0.04% |
| Mar 31, 2025 | -3.77% |
| Dec 31, 2024 | 7.15% |
| Sep 30, 2024 | 2.88% |
| Jun 30, 2024 | 1.44% |
| Mar 31, 2024 | -3.60% |
| Dec 31, 2023 | -10.57% |
| Sep 30, 2023 | -14.97% |
| Jun 30, 2023 | -19.65% |
| Mar 31, 2023 | -22.97% |
| Dec 31, 2022 | -21.26% |
| Sep 30, 2022 | -21.64% |
| Jun 30, 2022 | -17.67% |
| Mar 31, 2022 | -14.91% |
| Dec 31, 2021 | -18.75% |
| Sep 30, 2021 | -22.45% |
| Jun 30, 2021 | -26.84% |